Previous 10 | Next 10 |
2023-11-07 20:57:10 ET Veracyte, Inc. (VCYT) Q3 2023 Earnings Conference Call November 07, 2023 4:30 PM ET Company Participants Tristan Ribar – Vice President-Finance Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial O...
2023-11-07 16:23:47 ET More on Veracyte Veracyte: Testing Numbers Stretching Higher But Valuations Uncertain Seeking Alpha’s Quant Rating on Veracyte Historical earnings data for Veracyte Financial information for Veracyte For further details s...
Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023. “I am please...
Agreement is part of Veracyte’s multi-platform strategy for its decentralized IVD tests outside of the U.S. Veracyte, Inc . (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its h...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Veracyte Inc. (VCYT) is expected to report $-0.16 for Q3 2023
Veracyte, Inc . (Nasdaq: VCYT) announced today that Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 15, at 3:00 p.m. Eastern Time. A live audio webcast of the company’s presentations wi...
Two abstracts show the potential for using Veracyte’s tools to characterize the tumor microenvironment Veracyte, Inc. (Nasdaq: VCYT) today announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy of Cancer, in San ...
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2023 after the close of market on Tuesday, November 7, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business updat...
Two studies highlight the value of adding Envisia results to standard-of-care procedures for identifying patients at increased risk of progressive disease Veracyte, Inc . (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annua...
News, Short Squeeze, Breakout and More Instantly...
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update...
Findings presented at the ENDO 2024 conference Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive d...
Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from three studies will demonstrate the power of the Afirma GRID (Genomic Resource for Intelligent Discovery) tool to help unlock new molecular insights into thyroid tumors, which may ultimately help...